-
Big stakes on drug patents! -By Dean Baker
Last fall, India’s new Prime Minister, Narendra Modi, met with President Obama in Washington. According to the public accounts,...
-
Patents Against People: How Drug Companies Price Patients out of Survival – Courtesy (Dissent)
As our television screens toggle between pundits squabbling over Obamacare’s insurance rules and ads for erectile dysfunction remedies, another...
-
Amarantus Bioscience Receives Notice Of Allowance For U.S. Patent Application Covering Proprietary Compositions Of Matter And Methods Of Use for manufacture -Courtesy (Biospace)
SAN FRANCISCO and GENEVA, May 5, 2015 (GLOBE NEWSWIRE) — Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on...
-
Pluristem Therapeutics Inc Granted European Patent For Use Of Cells To Help Treat Damaged Bone Marrow – Courtesy (Biospace)
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced that it has been issued...
-
FDA Announces Major Proposed Rule Amending Hatch-Waxman Regulations – Courtesy (Hogan Lovells)
On February 6, 2015, the Food and Drug Administration (FDA) published in the Federal Register (FR) a comprehensive proposed...
-
Evaluating and improving orphan drug regulations in Europe: A Delphi policy study
1-s2-0-s0168851012002461-mainDownload
-
Federal Circuit Finds No Direct Infringement Of Akamai Patents – Courtesy (Pharma Patents)
POSTED BY COURTENAY C. BRINCKERHOFF ON 19 MAY 2015POSTED IN FEDERAL CIRCUIT DECISIONS;INFRINGEMENTThe Federal Circuit issued its remand decision in Akamai Technologies, Inc....
-
FDA To Give 5 Year NCE Exclusivity To Combinations – Courtesy (Pharma Patents)
POSTED BY COURTENAY C. BRINCKERHOFF ON 26 FEBRUARY 2014POSTED IN FDAIn a Federal Register Notice dated February 24, 2014, the U.S. FDA announced a...
